Grifols (GRFS) Competitors $9.74 -0.08 (-0.81%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$9.73 -0.01 (-0.10%) As of 09/19/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRFS vs. BNTX, TEVA, GMAB, SMMT, RDY, ASND, VTRS, QGEN, BBIO, and ROIVShould you be buying Grifols stock or one of its competitors? The main competitors of Grifols include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), QIAGEN (QGEN), BridgeBio Pharma (BBIO), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Grifols vs. Its Competitors BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris QIAGEN BridgeBio Pharma Roivant Sciences BioNTech (NASDAQ:BNTX) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership. Which has higher earnings and valuation, BNTX or GRFS? Grifols has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioNTech$2.98B7.77-$719.92M-$1.60-60.14Grifols$7.45B0.90$169.80M$1.178.32 Does the media refer more to BNTX or GRFS? In the previous week, BioNTech had 5 more articles in the media than Grifols. MarketBeat recorded 7 mentions for BioNTech and 2 mentions for Grifols. Grifols' average media sentiment score of 0.76 beat BioNTech's score of 0.57 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 3 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BNTX or GRFS more profitable? Grifols has a net margin of 0.00% compared to BioNTech's net margin of -12.20%. Grifols' return on equity of 0.00% beat BioNTech's return on equity.Company Net Margins Return on Equity Return on Assets BioNTech-12.20% -1.84% -1.59% Grifols N/A N/A N/A Which has more volatility & risk, BNTX or GRFS? BioNTech has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Do analysts prefer BNTX or GRFS? BioNTech presently has a consensus target price of $134.23, indicating a potential upside of 39.50%. Grifols has a consensus target price of $10.30, indicating a potential upside of 5.75%. Given BioNTech's stronger consensus rating and higher probable upside, analysts clearly believe BioNTech is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNTech 0 Sell rating(s) 3 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.79Grifols 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.60 Do insiders and institutionals hold more shares of BNTX or GRFS? 15.5% of BioNTech shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 0.2% of Grifols shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryGrifols beats BioNTech on 9 of the 17 factors compared between the two stocks. Get Grifols News Delivered to You Automatically Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRFS vs. The Competition Export to ExcelMetricGrifolsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.70B$2.53B$5.77B$10.45BDividend Yield1.45%55.05%5.61%4.56%P/E Ratio8.3223.0280.5026.82Price / Sales0.90484.84455.1691.38Price / Cash10.40172.2337.6661.43Price / Book0.725.3515.756.39Net Income$169.80M$32.95M$3.30B$271.80M7 Day Performance-1.42%0.90%5.35%3.51%1 Month Performance-3.37%4.71%7.28%9.58%1 Year Performance8.83%-2.98%80.79%28.53% Grifols Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRFSGrifols3.8386 of 5 stars$9.74-0.8%$10.30+5.7%+8.8%$6.70B$7.45B8.3223,822BNTXBioNTech2.5092 of 5 stars$97.88+1.2%$135.80+38.7%-14.3%$23.26B$2.98B-61.176,772TEVATeva Pharmaceutical Industries2.8923 of 5 stars$18.90-5.2%$24.71+30.8%+5.0%$22.86B$16.54B-118.1336,830Positive NewsGMABGenmab A/S3.7002 of 5 stars$27.99+0.6%$39.25+40.2%+10.8%$17.85B$3.12B14.072,682Positive NewsSMMTSummit Therapeutics3.1819 of 5 stars$18.94flat$33.79+78.4%-22.6%$14.07B$700K-18.75110Analyst ForecastRDYDr. Reddy's Laboratories2.5143 of 5 stars$14.64-0.2%$16.95+15.8%-5.4%$12.24B$3.81B22.1727,811Positive NewsASNDAscendis Pharma A/S2.733 of 5 stars$194.62-0.5%$244.36+25.6%+30.7%$11.97B$393.54M-37.721,017VTRSViatris1.1283 of 5 stars$9.60-3.6%$10.40+8.3%-13.1%$11.61B$14.74B-3.3132,000High Trading VolumeQGENQIAGEN4.4431 of 5 stars$45.39+0.2%$49.69+9.5%+5.3%$10.07B$1.98B26.825,765Positive NewsBBIOBridgeBio Pharma4.3352 of 5 stars$51.47+0.5%$63.94+24.2%+95.8%$9.79B$221.90M-12.58400ROIVRoivant Sciences3.4458 of 5 stars$13.95-0.9%$17.67+26.6%+25.6%$9.61B$29.05M-19.93860Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies BNTX Alternatives TEVA Alternatives GMAB Alternatives SMMT Alternatives RDY Alternatives ASND Alternatives VTRS Alternatives QGEN Alternatives BBIO Alternatives ROIV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRFS) was last updated on 9/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
